703-844-0184 | Ketamines Therapy Virginia for depression | Ketamine doctor Fairfax Virginia | Suicide is preventable: How can we help our teens?


Call 703-844-0184 for a phone consultation if you are interested in trying Ketamine for the treatment of depression, OCD, PTSD, or other mood disorders.

Security Code:
security code
Please enter the security code:

Submit

Suicide is preventable: How can we help our teens?

Social Rhythm Therapy (SRT)

Magic Medicine?

Patients are turning to ketamine and other psychoactive drugs for mental health treatment

Citocholine for Brain Health

Behind the Buzz: How Ketamine Changes the Depressed Patient’s Brain

References:

  1. Hamilton, J. Paul, et al. “Default-Mode and Task-Positive Network Activity in Major Depressive Disorder: Implications for Adaptive and Maladaptive Rumination.” Biological Psychiatry, vol. 70, no. 4, 2011, pp. 327–333., doi:10.1016/j.biopsych.2011.02.003.
  2. Kucyi, A., et al. “Enhanced Medial Prefrontal-Default Mode Network Functional Connectivity in Chronic Pain and Its Association with Pain Rumination.” Journal of Neuroscience, vol. 34, no. 11, 2014, pp. 3969–3975., doi:10.1523/jneurosci.5055-13.2014.
  3. Brewer, J. A., et al. “Meditation Experience Is Associated with Differences in Default Mode Network Activity and Connectivity.” Proceedings of the National Academy of Sciences, vol. 108, no. 50, 2011, pp. 20254–20259., doi:10.1073/pnas.1112029108.
  4. Scheidegger, Milan et al. “Ketamine Decreases Resting State Functional Network Connectivity in Healthy Subjects: Implications for Antidepressant Drug Action.” Ed. Stefano L. Sensi. PLoS ONE 7.9 (2012): e44799. PMC. Web. 23 June 2018.
  5. Sheline, Yvette I., et al. “The Default Mode Network and Self-Referential Processes in Depression.” Proceedings of the National Academy of Sciences, vol. 106, no. 6, 2009, pp. 1942–1947., doi:10.1073/pnas.0812686106.
  6. “Know Your Brain: Default Mode Network.” Neuroscientifically Challenged, 16 June 2015, www.neuroscientificallychallenged.com/blog/know-your-brain-default-mode-network.

References:

Krystal, J. H., Abdallah, C. G., Sanacora, G., Charney, D. S., & Duman, R. S. (2019). Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron, 101(5), 774-778. doi:10.1016/j.neuron.2019.02.005

According to the World Health Organization, depression has now surpassed HIV, AIDS, malaria, diabetes, and war as the leading cause of disability. Current antidepressants may take weeks to months to be effective. Unfortunately, one-third of patients are still unresponsive, and are called “treatment-resistant.” However, there are other options available.

References:

Choi, Miyeon, et al. “Ketamine Induces Brain-Derived Neurotrophic Factor Expression via Phosphorylation of Histone Deacetylase 5 in Rats.” Biochemical and Biophysical Research Communications, vol. 489, no. 4, 2017, pp. 420–425., doi:10.1016/j.bbrc.2017.05.157.

Lepack, A. E., et al. “BDNF Release Is Required for the Behavioral Actions of Ketamine.” International Journal of Neuropsychopharmacology, vol. 18, no. 1, 2014, doi:10.1093/ijnp/pyu033.

Réus, Gislaine, et al. “Ketamine Treatment Partly Reverses Alterations in Brain Derived- Neurotrophic Factor, Oxidative Stress and Energy Metabolism Parameters Induced by an Animal Model of Depression.” Current Neurovascular Research, vol. 12, no. 1, 2015, pp. 73–84., doi:10.2174/1567202612666150122122924.

Depression is among the most disabling conditions in our society. According to the World Health Organization, depression is the leading cause of ill health and disability worldwide. In America, 12.5% of individuals over the age of 12 have filled an antidepressant prescription.  Yet, the effectiveness of these medications are still lacking. Many patients don’t respond to antidepressant medications, and it can take months for the medicine to kick in. Unfortunately, many patients will regain their depression after being on medications long term.

References:

Choi, Miyeon, et al. “Ketamine Induces Brain-Derived Neurotrophic Factor Expression via Phosphorylation of Histone Deacetylase 5 in Rats.” Biochemical and Biophysical Research Communications, vol. 489, no. 4, 2017, pp. 420–425., doi:10.1016/j.bbrc.2017.05.157.

Lepack, A. E., et al. “BDNF Release Is Required for the Behavioral Actions of Ketamine.” International Journal of Neuropsychopharmacology, vol. 18, no. 1, 2014, doi:10.1093/ijnp/pyu033.

Réus, Gislaine, et al. “Ketamine Treatment Partly Reverses Alterations in Brain Derived- Neurotrophic Factor, Oxidative Stress and Energy Metabolism Parameters Induced by an Animal Model of Depression.” Current Neurovascular Research, vol. 12, no. 1, 2015, pp. 73–84., doi:10.2174/1567202612666150122122924.

REVISITING THE HALLUCINOGENIC POTENTIAL OF KETAMINE

WE NOW KNOW WHY KETAMINE IS SO EFFECTIVE AT TREATING DEPRESSION

FIRST KETAMINE INFUSION CLINIC IN PALM SPRINGS, CA OPENS

FROM CHAOS TO CALM: A LIFE CHANGED BY KETAMINE

IS KETAMINE THE NEXT BIG DEPRESSION DRUG?

KETAMINE RELIEVES DEPRESSION BY RESTORING BRAIN CONNECTIONS

IS KETAMINE THE BEST HOPE FOR CURING MAJOR DEPRESSION?

KETAMINE DEPRESSION TREATMENT ‘SHOULD BE ROLLED OUT’

KETAMINE: THE FUTURE OF DEPRESSION TREATMENT?

ONCE IT FULLY CATCHES ON, KETAMINE COULD BE A REALLY IMPORTANT ANTIDEPRESSANT

TACKLING DEPRESSION WITH KETAMINE

ONETIME PARTY DRUG HAILED AS MIRACLE FOR TREATING SEVERE DEPRESSION

YALE SCIENTISTS EXPLAIN HOW KETAMINE VANQUISHES DEPRESSION WITHIN HOURS

WHAT IT’S LIKE TO HAVE YOUR SEVERE DEPRESSION TREATED WITH A HALLUCINOGENIC DRUG

KETAMINE INFUSIONS CUT MIGRAINE PAIN IN HALF IN NEW STUDY

FOR RECALCITRANT NEUROPATHIC PAIN, CONSIDER OUTPATIENT KETAMINE

KETAMINE RESETS SYSTEM FOR NORMAL PAIN PROCESSING IN COMPLEX SYNDROME PATIENTS

FIBROMYALGIA DOCTOR TOUTS KETAMINE FOR PAIN AND DEPRESSION

FIBROMYALGIA PATIENTS TREATED WITH INTRAVENOUS KETAMINE

THIS COULD BE BIG: INTRAVENOUS KETAMINE FOR FIBROMYALGIA

THE CURRENT MENTAL HEALTH CRISIS AND THE COMING KETAMINE REVOLUTION

YALE: ‘MAGIC’ ANTIDEPRESSANT MAY HOLD PROMISE FOR PTSD

IV KETAMINE RAPIDLY EFFECTIVE IN PTSD

KETAMINE MAY HELP EXTINGUISH FEARFUL MEMORIES

KETAMINE COULD PROVE USEFUL IN TREATMENT OF SEVERE SOCIAL ANXIETY

PSYCHEDELIC MEDICINE 101: THE CURIOUS CASE OF KETAMINE

Links to Academic Articles

RAPID AND LONGER-TERM ANTIDEPRESSANT EFFECTS OF REPEATED KETAMINE INFUSIONS IN TREATMENT-RESISTANT MAJOR DEPRESSION

SAFETY AND EFFICACY OF REPEATED-DOSE INTRAVENOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION

NEUROBIOLOGY OF STRESS, DEPRESSION, AND RAPID ACTING ANTIDEPRESSANTS: REMODELING SYNAPTIC CONNECTIONS

NEW PARADIGMS FOR TREATMENT-RESISTANT DEPRESSION

ANTIDEPRESSANT EFFICACY OF KETAMINE IN TREATMENT-RESISTANT MAJOR DEPRESSION: A TWO-SITE RANDOMIZED CONTROLLED TRIAL

HIPPOCAMPAL VOLUME AND THE RAPID ANTIDEPRESSANT EFFECT OF KETAMINE

KETAMINE AND THE NEXT GENERATION OF ANTIDEPRESSANTS WITH A RAPID ONSET OF ACTION

DO THE DISSOCIATIVE SIDE EFFECTS OF KETAMINE MEDIATE ITS ANTIDEPRESSANT EFFECTS?

SYMPTOMATOLOGY AND PREDICTORS OF ANTIDEPRESSANT EFFICACY IN EXTENDED RESPONDERS TO A SINGLE KETAMINE INFUSION.

ANTIDEPRESSANT EFFECTS OF KETAMINE IN DEPRESSED PATIENTS

THE ROLE OF KETAMINE IN TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW

IMPROVEMENT IN SUICIDAL IDEATION AFTER KETAMINE INFUSION: RELATIONSHIP TO REDUCTIONS IN DEPRESSION AND ANXIETY

USE OF KETAMINE IN ACUTE CASES OF SUICIDALITY

A POSSIBLE ROLE FOR KETAMINE IN SUICIDE PREVENTION IN EMERGENCY AND MAINSTREAM PSYCHIATRY

EFFICACY OF INTRAVENOUS KETAMINE FOR TREATMENT OF CHRONIC POST-TRAUMATIC STRESS DISORDER: A RANDOMIZED CLINICAL TRIAL

EFFICACY OF KETAMINE IN THE TREATMENT OF SUBSTANCE USE DISORDERS: A SYSTEMATIC REVIEW

KETAMINE REDUCES MUSCLE PAIN, TEMPORAL SUMMATION, AND REFERRED PAIN IN FIBROMYALGIA PATIENTS

KETAMINE IN CHRONIC PAIN MANAGEMENT: AN EVIDENCE-BASED REVIEW

RANDOMIZED CONTROLLED CROSSOVER TRIAL OF KETAMINE IN OBSESSIVE-COMPULSIVE DISORDER: PROOF-OF-CONCEPT

RAPID RESOLUTION OF OBSESSIONS AFTER AN INFUSION OF INTRAVENOUS KETAMINE IN A PATIENT WITH TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER: A CASE REPORT

ANALGESIC EFFECT OF SUBANESTHETIC INTRAVENOUS KETAMINE IN REFRACTORY NEUROPATHIC PAIN: A CASE REPORT

PAIN ANALYSIS IN PATIENTS WITH FIBROMYALGIA. EFFECTS OF INTRAVENOUS MORPHINE, LIDOCAINE, AND KETAMINE

KETAMINE FOR SOCIAL ANXIETY DISORDER: A RANDOMIZED, PLACEBO-CONTROLLED CROSSOVER TRIAL

NOVEL TREATMENT FOR LEVODOPA INDUCED MOTOR FLUCTUATIONS AND DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE

KLEINE LEVIN SYNDROME (KLS) RESEARCH UPDATE IN LABORATORY OF DR. MIGNOT, STANFORD UNIVERSITY

Submit a Comment

Your email address will not be published. Required fields are marked *